Evidence Snapshot

ROS1-SDC4

CHEMBL5303568 CHIMERIC PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:06:29Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:06 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL5303568

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats ROS1-SDC4 as ChEMBL target CHEMBL5303568, mapped to UniProt P08922. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

ROS1-SDC4

CHIMERIC PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL5303568

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P08922

Proto-oncogene tyrosine-protein kinase ROS

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why ROS1-SDC4 matters

As of 2026-09-13

ROS1-SDC4 is reviewed as Proto-oncogene tyrosine-protein kinase ROS (UniProt P08922); ROS1-SDC4 shows approved-linked disease relevance led by cancer. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 2 compounds, and 1 assay, with lead potency reaching pChEMBL 7.8.

Protein context

Proto-oncogene tyrosine-protein kinase ROS

Proto-oncogene tyrosine-protein kinase ROS Sequence length is 2347 aa.

Review this target as ROS1-SDC4, mapped to UniProt P08922. ChEMBL maps the protein component as Proto-oncogene tyrosine-protein kinase ROS. Sequence length is 2347 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P08922 Protein

Disease context

cancer

ROS1-SDC4 shows approved-linked disease relevance led by cancer. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include REPOTRECTINIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REPOTRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 2 compounds, and 1 assay for this target. The dominant activity type is IC50. CHEMBL3545311 is the current potency anchor at pChEMBL 7.8.

Use CHEMBL3545311 as the tractability anchor when discussing potency (pChEMBL 7.8).

Activity source · ChEMBL 36 via Core Engine

2 approved pChEMBL 7.8

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why ROS1-SDC4 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08922, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

IC50: 2.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure	Compound	pChEMBL	Type	Phase
	No preferred name CHEMBL3545311	7.8	IC50	Approved
	No preferred name CHEMBL601719	7.8	IC50	Approved